scispace - formally typeset
Journal ArticleDOI

Cystic fibrosis mutation analysis: Report from 22 U.K. regional genetics laboratories

Reads0
Chats0
TLDR
The data illustrate that the mutations present within a particular population need to be defined in order to provide meaningful carrier screening and testing for rare mutations in affected individuals and it is apparent that the ethnic origin of a patient, even within a small country such as the United Kingdom, should be taken into account.
Abstract
We have collated the results of cystic fibrosis (CF) mutation analysis conducted in 22 laboratories in the United Kingdom. A total of 9,807 CF chromosomes have been analysed, demonstrating 56 different mutations so far observed and accounting for 86% of CF genes in the native Caucasian population of the United Kingdom. ΔF508 is the most common at 753% of CF mutations (range 56.5–83.7%), followed by G551D (3.08%; range 0.71–7.60%), G542X (1.68%; range 0.85–3.66%), 621 + 1 (G>T) (0.93%; range 0.41–3.16%), 1717-1(G>A) (0.57%; range 0.17-1.14%), 1898+ 1)(G>A) (0.46%), R117H (0.46%), N1303K (0.46%), and R553X (0.46%). The data show a clear geographical variation in the distribution of some of the mutations, most notably a marked regional variation in the distribution of 621 + 1 (G>T)and 1989+ 1(G>A), which are both apparently more frequent in Wales. R560T and R117H appear to be more frequent in Ireland and Scotland, and G551D more frequent in Scotland. In summary, these data illustrate that the mutations present within a particular population need to be defined in order to provide meaningful carrier screening and testing for rare mutations in affected individuals. Furthermore, it is apparent that the ethnic origin of a patient, even within a small country such as the United Kingdom, should be taken into account. © 1995 Wiley-Liss, Inc.

read more

Citations
More filters
Journal ArticleDOI

Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.

TL;DR: From comprehensive assessment of data, it is offered recommendations that multiple CFTR alleles should eventually be included to increase the sensitivity of newborn screening programs employing two‐tier testing with trypsinogen and DNA analysis.
Journal ArticleDOI

Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations

TL;DR: Overall 55 mutations are common in one or several countries or regions of Europe and 217 mutations are rare with relative frequencies of lower than 1% in any of these regions and countries.
Journal ArticleDOI

Neonatal screening for inborn errors of metabolism: cost, yield and outcome

TL;DR: The majority of economic evaluations failed to incorporate the health benefits from screening, and therefore failed to address the value of the information which the screening programmes provided to parents.
References
More filters
Journal ArticleDOI

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

TL;DR: A deletion of three base pairs that results in the omission of a phenylalanine residue at the center of the first predicted nucleotide-binding domain was detected in CF patients.
Journal ArticleDOI

Identification of the cystic fibrosis gene: genetic analysis.

TL;DR: Extended haplotype data based on DNA markers closely linked to the putative disease gene locus suggest that the remainder of the cystic fibrosis mutant gene pool consists of multiple, different mutations.
Journal ArticleDOI

Identification of the cystic fibrosis gene: Chromosome walking and jumping

TL;DR: Several transcribed sequences and conserved segments were identified in this cloned region and one corresponds to the cystic fibrosis gene and spans approximately 250,000 base pairs of genomic DNA.
Journal ArticleDOI

Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene.

TL;DR: The highly heterogeneous nature of the remaining CF mutations provides important insights into the structure and function of the protein, but it also suggests that DNA-based genetic screening for CF carrier status will not be straightforward.
Related Papers (5)